Depletion of Paneth cells is associated with decreased portal hypertension and angiogenesis after partial portal vein ligation in mice.
EASL LiverTree™, Mohsin Hassan, 207335
A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy
EASL LiverTree™, Vincenza Di Gregorio, 207336
Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement
EASL LiverTree™, Rohit Loomba, 207337
The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa.    
EASL LiverTree™, William Alazawi, 207351
Secreted ectodomain of SIGLEC-9 and MCP-1 ameliorate acute liver failure in rats by altering bone marrow macrophage polarity
EASL LiverTree™, Takanori Ito, 207354
Hepatic outcomes from childhood intestinal failure: a meta-analysis of 8223 patients
EASL LiverTree™, Aureliane Pierret, 207368
Comparison between Room-Temperature Susceptometry and MRI with respect to the cell-specific detection of liver iron
EASL LiverTree™, Johannes Mueller, 207370
Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patientes with severe alpha1-antitrypsin-deficiency
EASL LiverTree™, Carolin Victoria Heimes, 207371
Impact of acute hepatic porphyrias on quality of life and work loss: an analysis of EXPLORE natural history study
EASL LiverTree™, Sonalee Agarwal, 207372
Clinical response after laparoscopic fenestration of large simple hepatic cysts: a systematic review
EASL LiverTree™, Lucas Bernts, 207385
Pertinence of liver stiffness measurement inpatients with Wilson's disease for assessment of initial fibrosis and treatmentfollow-up
EASL LiverTree™, Rodolphe Sobesky, 207386
Clinicalpresentation and outcome of Wilson’s disease patients in a monocentric cohort ofliver reference center
EASL LiverTree™, Rodolphe Sobesky, 207387
The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease
EASL LiverTree™, Thomas Damgaard Sandahl, 207390
Evaluation of Multiparametric MRI in comparison with MR Elastography in patients evaluated for chronic liver disease
EASL LiverTree™, Stephen Bravo, 207406
Glomerular filtration rate evaluation in patients with cirrhosis, which equation shall be used in clinical daily practice?
EASL LiverTree™, Sofia Monteiro, 207407
Predictions from a very hard liver: the role of liver stiffness in alcoholic hepatitis  
EASL LiverTree™, Petra Fischer, 207408
Soluble serum vascular adhesion protein (sVAP)-1: a new biomarker in primary sclerosing cholangitis?
EASL LiverTree™, Francesca Saffioti, 207409
Non invasive diagnostic approach for screening and grading of portal hypertension in patients with advanced liver disease.
EASL LiverTree™, Sergii Kozlov, 207423
Circulating micro-ARNs as biomarkers of alcohol liver disease and hepatocellular carcinoma
EASL LiverTree™, Charles-Antoine PAPILLON, 207424
Liver function assessment using magnetic resonance imaging with gadoxetic acid administration
EASL LiverTree™, Christina Levick, 207425
Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity
EASL LiverTree™, Christina Levick, 207426
Induction of beta-catenin in embryonic stem cell-derived dendritic cells alleviates liver damage in mouse liver inflammatory injury
EASL LiverTree™, Bibo Ke, 207445
Sealant pathology
EASL LiverTree™, Omid Ghamar Nejad, 207446
Preoperative biliary drainage reverses cholestasis-associated inflammatory and fibrotic gene signatures in patients with perihilar cholangiocarcinoma
EASL LiverTree™, Rowan van Golen, 207447
Distinct functions of phosphorylated and un-phosphorylated STAT1 in hepatocellular carcinoma
EASL LiverTree™, Buyun Ma, 207448
Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma
EASL LiverTree™, Eva Benabou, 207462
Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma
EASL LiverTree™, Barbara Oliviero, 207463
Difference of gene mutational profile among viral- and non-viral HCC with  or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration
EASL LiverTree™, Fukiko Kawai-Kitahata, 207464
Therapeutics of cell-specific MAPK modulation in chronic liver disease using (siJNK2) nanodelivery
EASL LiverTree™, Marius Maximilian Woitok, 207465
Mitochondrial VDAC1 based peptide as a new therapeutic agent for hepatocellular carcinoma 
The role of Lysyl oxidase in tumor microenvironment of primary liver cancer
EASL LiverTree™, Monika Lewinska, 207482
The anti-inflammatory receptor TREM2 halts the generation of HCC in mice through the inhibition of liver inflammation and hepatocyte proliferative responses
EASL LiverTree™, María Jesús Perugorria, 207483
Functional genomics identified actin cytoskeleton remodeling required for the hypoxia-mediated EMT: a mechanistic link of tumor size to metastasis
EASL LiverTree™, Sen-Yung Hsieh, 207484
High miR-224 expression in cholangiocarcinoma may predict survival 
EASL LiverTree™, Tímea Szekerczés, 207498
Do extracellular vesicles secreted from senescent hepatic stellate cells promote or suppress cancer development?
EASL LiverTree™, Yuri Miyazoe, 207499
The role of IL-6 signaling pathway in cholangiocarcinoma
EASL LiverTree™, Ruben Plentz, 207500
A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma
EASL LiverTree™, Riccardo Patti, 207502
Determinants of clinical efficacy of empirical antibiotic treatment in patients with cirrhosis and bacterial infections: Results from the ICA Global study
EASL LiverTree™, Rakhi Maiwall, 207517
The mechanism of irreversibility of late stage cirrhosis
EASL LiverTree™, Ian R. Wanless, 207518
Assessing Baveno VI criteria with a new point-shear wave elastography technique: the BAVElastPQ study
EASL LiverTree™, Giulia Gibiino, 207520
Loss of Subcutaneous Adipose Tissue Associates with Higher Mortality Risk in Patients with Cirrhosis
EASL LiverTree™, Aldo J. Montano-Loza, 207534
Assessment of biventricular function in patients with decompensated cirrhosis and hepatopulmonary syndrome
EASL LiverTree™, Stergios Soulaidopoulos, 207535
EASL LiverTree™, Stefania Gioia, 207537
Thromboelastography guided blood product transfusion in cirrhosis patients with acute variceal bleeding: a Randomized Controlled Trial
EASL LiverTree™, Gyanranjan Rout, 207550
Non-selective beta-blockers increase liver mortality when MELD is ≥12 in a prospective 5 year follow-up cohort of alcoholic cirrhosis
EASL LiverTree™, Paul Cales, 207552
Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort
EASL LiverTree™, Apurva Yeluru, 207553
Distinct MELD Trajectories in Liver Transplant Candidates with Hepatitis C and NASH
EASL LiverTree™, Allison Kwong, 207566
Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial
EASL LiverTree™, Rafael Paternostro, 207568
Varices on CT is the surrogate of clinically significant portal hypertension and can predict survival in patients with cirrhosis
EASL LiverTree™, Dong Ho Lee, 207569
Predictors of Endoscopic High Risk EsophagealVarices in Compensated Cirrhosis: Can we Avoid Fibroscan?
EASL LiverTree™, Julian Hercun, 207570
Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant
EASL LiverTree™, Brooke Chapman, 207588
Dynamic Visual Processing in Patients with Decompensated Cirrhosis
EASL LiverTree™, Katherine Wong, 207589
The physical component of the SF-36 Quality of Life tool is an independent predictor of mortality in patients with severe ascites
EASL LiverTree™, Stewart Macdonald, 207590
Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: a systematic review and meta-analysis
EASL LiverTree™, Susana Rodrigues, 207603
Clinically significant portal hypertension in chronic liver disease: always cirrhosis?
EASL LiverTree™, Susana Rodrigues, 207604
Screening of esophagogastric varices: performance of the 'Expanded Baveno VI criteria' and the 'platelet 150/MELD 6' strategy in all etiology compensated advanced chronic liver disease
EASL LiverTree™, giulia tosetti, 207605
Combined elastin and collagen proportionate area (ECPA) sub-classifies cirrhosis and predicts clinical outcomes
EASL LiverTree™, Avik Majumdar, 207606
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is highly effective in patients with a MELD score < 20 and does not require routine Doppler ultrasound follow-up
EASL LiverTree™, Koos de Wit, 207607
Transjugular Intrahepatic Portosystemic Shunt Versus Beta-blocker and/or Endotherapy  for Prevention of Variceal Rebleeding in adults with EHPVO
EASL LiverTree™, Guohong Han, 207620
A prospective evaluation of symptom burden,opioid risk in cirrhosis patients
EASL LiverTree™, Mina Niazi, 207622
Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures. 
EASL LiverTree™, Javier Ampuero, 207623
Four years outcomes of Baveno VI low risk cirrhotic patients
EASL LiverTree™, Priscila Pollo Flores, 207624
A novel sonographic parameter for the quantification of muscle mass in cirrhosis
EASL LiverTree™, Kazufumi Kobayashi, 207625
Cardiac assessment in children with chronic liver disease: cholestatic and non-cholestatic 
EASL LiverTree™, Tawhida Abdel Ghaffar, 207637
Non-invasive predictors of varices in non-cirrhotic portal hypertension
EASL LiverTree™, Morven Cunningham, 207638
Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis 
EASL LiverTree™, Graziella Privitera, 207639
Drug-induced encephalopathy in cirrhotic patients with neurological symptoms: a metabolomic study.
EASL LiverTree™, Nicolas Weiss, 207640
Incidence of hepatitis E infection in renal transplant patients in The Netherlands
EASL LiverTree™, robin erken, 207657
Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A
EASL LiverTree™, Slim Fourati, 207659
HBV Peptide Array Demonstrates Candidate Mechanisms of CRV431 Anti-HBV Activity
EASL LiverTree™, Robert Foster, 207675
Assessing the in vitro anti-HBV activity of combinations including CRV431,  TXL, and  prototype capsid assembly modulators
EASL LiverTree™, Robert Foster, 207676
Establishment of a method to compare antiviral effect of drug products by human hepatitis B virus infected humanized chimeric mice
EASL LiverTree™, Hatsune Enomoto, 207677
Identification of HBV genotypes and mutations associated to antiviral resistance and vaccine escape in serum and oral fluid samples from chronic hepatitis B patients
EASL LiverTree™, Moyra Machado Portilho, 207678
Hepatitis B virus escapes non-canonical CTL effector function
EASL LiverTree™, Percy A. Knolle and Dirk Wohlleber, 207691
HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients 
EASL LiverTree™, Kai-Henrik Peiffer, 207692
Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation
EASL LiverTree™, Florian Lempp, 207693
Proteomic analysis of hepatitis B virus cccDNA-specific associated proteins identifies crucial regulators of viral transcription and RNA processing
EASL LiverTree™, Barbara Testoni, 207694
Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling appraoch
EASL LiverTree™, Harel Dahari, 207710
Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains
EASL LiverTree™, Athenaïs Gerber, 207712
Deep sequencing analysis highlights variations associated with HBeAg seroconversion in adolescents with chronic hepatitis B
EASL LiverTree™, Christophe Combet, 207713
Induction of liver sinusoidal endothelial cells immune activation by HBeAg during HBV infection
EASL LiverTree™, Jia Liu, 207728
Regulation of antiviral CD8 T cell response by MMP mediated soluble CD100 releasing in HBV infection
EASL LiverTree™, Jia Liu, 207729
Hepatitis B virus entry in primary human hepatocytes initiates toll-like receptor 2-dependent immune signaling.
EASL LiverTree™, Ruth Broering, 207732
Characterization of theHEV-specific CD8+ T-cell response in acute and chronic Hepatitis E virus infection
EASL LiverTree™, Janine Kemming, 207748
Performance of recomWell HEV and Wantai HEV in acute Hepatitis E and German blood donors
EASL LiverTree™, Friedhelm Struck, 207750
Ex vivo characterization of co-inhibitory molecules on MHC class II tetramer positive HCV-specific CD4+ T cells in HCV infection
EASL LiverTree™, Christin Ackermann, 207751
Delineating Complement Activation Molecular Patterns in Patients with Alcoholic Hepatitis
EASL LiverTree™, Rebecca McCullough, 207765
Presence of IgA isotype F-actin is frequent in patients with cirrhosis and consitutes the risk of progressive disease course
EASL LiverTree™, Boglárka Balogh, 207766
Substantial healthcare utilization (HCU) and costs among non-alcoholic steatohepatitis (NASH) patients with comorbid diabetes mellitus (DM): Real-world analysis of 2007-2015 US Medicare data
EASL LiverTree™, Stuart Gordon, 207783
Prediction of decompensation events in NASH cirrhosis patients
EASL LiverTree™, Roberta Forlano, 207784
Lipofuscin is detected in early  stages of the disease in liver biopsies of patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Roberta Forlano, 207786
Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH)
EASL LiverTree™, Elena Buzzetti, 207800
EASL LiverTree™, Giampaolo Bianchi, 207801
Do patients with abnormal liver tests and nonalcoholic fatty liver disease get statins even when indicated?
EASL LiverTree™, Russell Rosenblatt, 207802
The effect of microvascular complications of diabetes on advanced fibrosis in nonalcoholic fatty liver disease
EASL LiverTree™, Russell Rosenblatt, 207803
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in Patienst with Advanced Fibrosis/Compensated Cirrhosis
EASL LiverTree™, Salvatore Petta, 207818
A Comprehensive Assessment of Serial Transient elastography in various Liver disease Etiologies at the Toronto Liver Centre (CASTLE-TLC)
EASL LiverTree™, Kerstina Boctor, 207819
Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients.
EASL LiverTree™, Amalia Gastaldelli, 207820
The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM)
EASL LiverTree™, Zobair Younossi, 207834
Moderate Alcohol Consumption Protects Against Fatty Liver in Males
EASL LiverTree™, Takemi Akahane, 207835

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings